Totaligent Inc. (OTC: TGNT) has executed a binding Letter of Intent with GloMed Solutions, a Japanese distributor of medical aesthetics and biologics products with approximately $10 million in annual revenue. The agreement establishes a joint venture structure that will integrate Totaligent's Aetherium Medical platform with GloMed's existing operations and market presence in Japan, a key market for medical aesthetics and biologics distribution.
Under the terms of the binding agreement, Totaligent has secured a call option to acquire full ownership of GloMed Solutions within one year, providing the company with a defined pathway to full consolidation of the business. The joint venture is anticipated to close around March 22, 2026, subject to customary closing conditions and regulatory approvals.
The transaction positions Totaligent to expand its footprint in the high-growth medical aesthetics and biologics sectors, leveraging GloMed's established distribution network and operational infrastructure in Japan. The move represents a strategic entry into a market experiencing sustained demand for advanced medical aesthetic and biologic therapies.